ARMOOTCinactive

ARMO BIOSCIENCES, INC.

Healthcare·Oncology·Phase 2
Oncology

ARMO BIOSCIENCES, INC. (ARMO): 5 pipeline candidates · ~27 mo cash runway. Updated within the last hour.

8.0/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway7.5

27.1 months

Financial Health10.0

0% dilution

Pipeline Maturity6.0

Lead: Phase 2

Pipeline Breadth8.5

5 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for ARMO BIOSCIENCES, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

Cash

$165.4M

Quarterly Burn

$18.5M

Runway

27.1 mo

Revenue

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Sep 2028
Today~30 mo out
Catalyst within runway

Pipeline (5 candidates)

Frequently asked questions

How many drug candidates are in ARMO BIOSCIENCES, INC.'s pipeline?

ARMO BIOSCIENCES, INC. (ARMO) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is ARMO BIOSCIENCES, INC.'s lead drug candidate?

ARMO BIOSCIENCES, INC.'s most advanced tracked candidate is am0001 (Preclinical) for Advanced malignancies.

What is ARMO BIOSCIENCES, INC.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, ARMO BIOSCIENCES, INC. has approximately 27.1 months of cash runway.

Get the full picture on ARMO BIOSCIENCES, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.